GoAI
Get started
Glass House Brands Inc logo

Glass House Brands Inc

GLAS

NYSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$9.79

+$0.27 · +2.84%

Aug 21, 4:00 PM ET

Pre-market

$9.85

+$0.06 · +0.61%

Aug 24, 7:00 AM ET

GLAS company overview

Regular session · ET · Market data may be delayed.

Company profile

Company website

Glass House Brands, Inc. operates as an integrated cannabis company in the United States with focus on the California market and building brands to serve consumers across various segments. The company is involved in greenhouse cultivation operations, manufacturing practices, brand-building, and retailing activities. The company offers its cannabis products through its portfolio of brands, which includes Glass House Farms, PLUS Products, Allswell, Forbidden Flowers, and Mama Sue Wellness. The company was founded by Kyle Kazan, Graham Farrar and Jocelyn Rosenwald in 2015 and is headquartered in Long Beach, CA.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Kyle Kazan
Listed since
Jun 30, 2026
Employees
392

Market position

Day range

Current $9.79

52-week range

Current $9.79

Open
$9.50
Previous close
$9.52
Volume
230.02K
0.64× average
Average volume
361.53K
Average daily volume
Market cap
758M USD
Beta
0.51
Market reference 1
50-day average
$11.86
-17.45% below average
200-day average
$11.86
-17.45% below average

Earnings

EPS beat rate
44%
4 beats, 5 misses, 0 met estimates
Average EPS surprise
-65.99%
9 comparable reports
Latest EPS result
-0.08
Estimate -0.08 · Miss by 4.34%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.20.05-0.1-0.24Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 25, 2025: actual 0.157, estimate -0.105, surprise +249.64%, Beat. Q2 2025, reported May 13, 2025: actual -0.18, estimate -0.145, surprise -24.14%, Miss. Q3 2025, reported Aug 13, 2025: actual 0.05, estimate -0.055, surprise +191.66%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.15, estimate -0.175, surprise +14.29%, Beat. Q1 2026, reported Mar 24, 2026: actual -0.203, estimate -0.19, surprise -6.71%, Miss. Q2 2026, reported May 13, 2026: actual -0.2, estimate -0.175, surprise -14.29%, Miss. Q3 2026, reported Aug 12, 2026: actual -0.08, estimate -0.077, surprise -4.34%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.013, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates62.26M52.68M43.09M33.51MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 25, 2025: actual 53.04M USD, estimate 50.38M USD, surprise +5.28%, Beat. Q2 2025, reported May 13, 2025: actual 44.82M USD, estimate 43.4M USD, surprise +3.27%, Beat. Q3 2025, reported Aug 13, 2025: actual 59.87M USD, estimate 58.1M USD, surprise +3.04%, Beat. Q4 2025, reported Nov 12, 2025: actual 38.44M USD, estimate 35.9M USD, surprise +7.09%, Beat. Q1 2026, reported Mar 24, 2026: actual 38.86M USD, estimate 38.8M USD, surprise +0.14%, Beat. Q2 2026, reported May 13, 2026: actual 40.52M USD, estimate 40.15M USD, surprise +0.91%, Beat. Q3 2026, reported Aug 12, 2026: actual 47.02M USD, estimate 54.43M USD, surprise -13.61%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate 52.81M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$16.00

63.43% upside
Past 12 months12-month forecastHigh $17.00Average $16.00Low $15.00

Continue in GoAI

Research GLAS

research.disclaimer